Arkadios Wealth Advisors Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Arkadios Wealth Advisors purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,132 shares of the biopharmaceutical company's stock, valued at approximately $264,000.

Other large investors have also made changes to their positions in the company. XTX Topco Ltd grew its holdings in shares of Halozyme Therapeutics by 27.0% during the first quarter. XTX Topco Ltd now owns 18,370 shares of the biopharmaceutical company's stock worth $1,172,000 after buying an additional 3,911 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new position in shares of Halozyme Therapeutics in the 1st quarter valued at $89,000. Mackenzie Financial Corp increased its stake in shares of Halozyme Therapeutics by 392.1% in the 1st quarter. Mackenzie Financial Corp now owns 85,609 shares of the biopharmaceutical company's stock valued at $5,463,000 after purchasing an additional 68,213 shares during the last quarter. LPL Financial LLC lifted its holdings in Halozyme Therapeutics by 17.1% during the 1st quarter. LPL Financial LLC now owns 242,432 shares of the biopharmaceutical company's stock worth $15,470,000 after buying an additional 35,429 shares during the period. Finally, TD Asset Management Inc lifted its holdings in Halozyme Therapeutics by 5.8% during the 1st quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company's stock worth $92,642,000 after buying an additional 79,708 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.80 during midday trading on Friday, reaching $62.90. 1,592,672 shares of the stock traded hands, compared to its average volume of 1,612,448. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.50. The firm has a market cap of $7.75 billion, a price-to-earnings ratio of 14.39, a PEG ratio of 0.38 and a beta of 1.17. The firm has a fifty day moving average price of $55.98 and a two-hundred day moving average price of $57.95. The company has a current ratio of 8.36, a quick ratio of 7.30 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same quarter in the prior year, the business earned $0.91 EPS. The company's revenue for the quarter was up 40.8% compared to the same quarter last year. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a research note on Tuesday, May 13th. The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 target price for the company. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Finally, JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a report on Thursday. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $66.56.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $41,403,763.17. This represents a 2.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 60,000 shares of company stock valued at $3,262,400. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.